Malamut Richard
Malamut Richard's purchase track record
Malamut Richard has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/12/2024 | PTHS | $10K | -29.7% | +74.5% | -1.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
COLL Outlook Supported by ADHD Trends, Low Generic Risk, Oppenheimer. Oppenheimer notes that Collegium Pharmaceutical's outlook is bolstered by strong demand for ADHD treatments and a low risk of generic competition. The firm’s focus on these areas may help sustain revenue growth. The stock is currently trading near its 52‑week low of $21.43, close to a support level that has been tested repeatedly.
Transaction History
| PTHS | ▼ Sell | Open Market | 310 | $6K | 4/2/2026 | View on chart |
| PTHS | ▼ Sell | Open Market | 280 | $6K | 4/2/2026 | View on chart |
| PTHS | ▲ Buy | Open Market | 10,400 | $10K | 9/12/2024 | View on chart |
| COLL | ▲ Buy | Grant | 6,256 | — | 2/10/2022 | View on chart |
| COLL | ▲ Buy | Grant | 36,750 | $0 | 2/10/2022 | View on chart |
| COLL | ▼ Sell | Tax Withholding | 4,462 | $79K | 2/10/2022 | View on chart |
| COLL | ▼ Sell | Tax Withholding | 1,838 | $32K | 2/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Pelthos Expands Coverage for ZELSUVMI Topical Gel
Pelthos Therapeutics announced that its topical gel ZELSUVMI® will now be covered by more insurance plans. The broader formulary coverage could make the product more accessible to patients. This change may support the company’s sales growth for the drug. The update follows the company’s recent progress in bringing the therapy to market.
Pelthos Expands Coverage for ZELSUVMI Topical Gel. Pelthos Therapeutics announced that its topical gel ZELSUVMI® will now be covered by more insurance plans. The broader formulary coverage could make the product more accessible to patients. This change may support the company’s sales growth for the drug. The update follows the company’s recent progress in bringing the therapy to market.